These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

579 related items for PubMed ID: 19563407

  • 1.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 2.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 3. Expression of glucose transporter protein 1 and p63 in serous ovarian tumor.
    Cai Y, Zhai JJ, Feng BB, Duan XZ, He XJ.
    J Obstet Gynaecol Res; 2014 Jul; 40(7):1925-30. PubMed ID: 25056472
    [Abstract] [Full Text] [Related]

  • 4. Progressive loss of selenium-binding protein 1 expression correlates with increasing epithelial proliferation and papillary complexity in ovarian serous borderline tumor and low-grade serous carcinoma.
    Zhang C, Wang YE, Zhang P, Liu F, Sung CJ, Steinhoff MM, Quddus MR, Lawrence WD.
    Hum Pathol; 2010 Feb; 41(2):255-61. PubMed ID: 19896693
    [Abstract] [Full Text] [Related]

  • 5.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 6. Vascular endothelial growth factor expression in serous ovarian carcinoma: relationship with high mitotic activity and high FIGO stage.
    Brustmann H, Naudé S.
    Gynecol Oncol; 2002 Jan; 84(1):47-52. PubMed ID: 11748975
    [Abstract] [Full Text] [Related]

  • 7. [Expression and significance of GLUT-1 and DNA-PKcs in serous ovarian tumors].
    Cai Y, Shao SL, Wang QH, Yan LJ, Wang XY, Wang LX.
    Ai Zheng; 2007 Nov; 26(11):1188-93. PubMed ID: 17991316
    [Abstract] [Full Text] [Related]

  • 8. Increased serum 72 KDa metalloproteinase in serous ovarian tumors: comparison with CA 125.
    Garzetti GG, Ciavattini A, Lucarini G, Goteri G, Romanini C, Biagini G.
    Anticancer Res; 1996 Nov; 16(4A):2123-7. PubMed ID: 8712754
    [Abstract] [Full Text] [Related]

  • 9. DNA fragmentation factor (DFF45): expression and prognostic value in serous ovarian cancer.
    Brustmann H.
    Pathol Res Pract; 2006 Nov; 202(10):713-20. PubMed ID: 16962250
    [Abstract] [Full Text] [Related]

  • 10. [Correlation of hK6 expression with clinicopathological features and prognosis in epithelial ovarian cancer].
    Hu CJ, Zhang F, Chen YJ, Sun XM, Zheng JF.
    Zhonghua Zhong Liu Za Zhi; 2009 Jul; 31(7):520-3. PubMed ID: 19950700
    [Abstract] [Full Text] [Related]

  • 11. Expression of extracellular matrix proteins in ovarian serous tumors.
    Salani R, Neuberger I, Kurman RJ, Bristow RE, Chang HW, Wang TL, Shih IeM.
    Int J Gynecol Pathol; 2007 Apr; 26(2):141-6. PubMed ID: 17413980
    [Abstract] [Full Text] [Related]

  • 12. B7-H4 overexpression in ovarian tumors.
    Tringler B, Liu W, Corral L, Torkko KC, Enomoto T, Davidson S, Lucia MS, Heinz DE, Papkoff J, Shroyer KR.
    Gynecol Oncol; 2006 Jan; 100(1):44-52. PubMed ID: 16256178
    [Abstract] [Full Text] [Related]

  • 13. High expression of tissue inhibitor of metalloproteinase-2 in serous ovarian carcinomas and the role of this expression in ovarian tumorigenesis.
    Kim TJ, Rho SB, Choi YL, Choi CH, Lee JW, Bae DS, Ahn G, Lee JH, Kim BG.
    Hum Pathol; 2006 Jul; 37(7):906-13. PubMed ID: 16784992
    [Abstract] [Full Text] [Related]

  • 14. [Expression of GLUT-1, p63 and DNA-Pkcs in serous ovarian tumors and their significance].
    Shao SL, Cai Y, Wang QH, Yan LJ, Zhao XY, Wang LX.
    Zhonghua Zhong Liu Za Zhi; 2007 Sep; 29(9):697-700. PubMed ID: 18246802
    [Abstract] [Full Text] [Related]

  • 15. [Expressions of Cx43 and Skp2 in epithelial ovarian tumor and their clinical significances].
    Hu YQ, Liu YJ.
    Ai Zheng; 2005 Jan; 24(1):104-9. PubMed ID: 15642212
    [Abstract] [Full Text] [Related]

  • 16. Nanog is highly expressed in ovarian serous cystadenocarcinoma and correlated with clinical stage and pathological grade.
    Pan Y, Jiao J, Zhou C, Cheng Q, Hu Y, Chen H.
    Pathobiology; 2010 Jan; 77(6):283-8. PubMed ID: 21266826
    [Abstract] [Full Text] [Related]

  • 17. [Expression and clinical relevance of ARHI, STAT3 and E2F1 in ovarian serous carcinoma].
    Zhang J, Li YH, Cui AR, Wang JL, Cheng JX, Wang SJ.
    Zhonghua Zhong Liu Za Zhi; 2008 Dec; 30(12):905-9. PubMed ID: 19173990
    [Abstract] [Full Text] [Related]

  • 18. An immunohistochemical comparison between low-grade and high-grade ovarian serous carcinomas: significantly higher expression of p53, MIB1, BCL2, HER-2/neu, and C-KIT in high-grade neoplasms.
    O'Neill CJ, Deavers MT, Malpica A, Foster H, McCluggage WG.
    Am J Surg Pathol; 2005 Aug; 29(8):1034-41. PubMed ID: 16006797
    [Abstract] [Full Text] [Related]

  • 19. Vascular endothelial growth factor expression in serous ovarian carcinoma: relationship with topoisomerase II alpha and prognosis.
    Brustmann H.
    Gynecol Oncol; 2004 Oct; 95(1):16-22. PubMed ID: 15385105
    [Abstract] [Full Text] [Related]

  • 20. Prostate-derived Ets factor is overexpressed in serous epithelial ovarian tumors.
    Rodabaugh KJ, Mhawech-Fauceglia P, Groth J, Lele S, Sood AK.
    Int J Gynecol Pathol; 2007 Jan; 26(1):10-5. PubMed ID: 17197890
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 29.